X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the acquisition, Eli gains access to Emergence's ADC pipeline, including ETx-22 (enfortumab vedotin), which targets Nectin-4 and is being developed for bladder, triple-negative breast cancer and malignancies with moderate and low Nectin-4 expression levels.
Lead Product(s): Enfortumab Vedotin
Therapeutic Area: Oncology Product Name: ETx-22
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition June 29, 2023
Details:
Emergence will be responsible for the research, development, manufacturing and commercialization of the ADCs. Synaffix will be responsible for the manufacturing of components that are specifically related to its proprietary technologies.
Lead Product(s): Antibody-drug Conjugate
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: Synaffix
Deal Size: Undisclosed Upfront Cash: $360.0 million
Deal Type: Licensing Agreement September 06, 2022
Details:
Proceeds from this funding round will be used to advance the company’s next-generation antibody drug conjugate (ADC) including ETx-22, targeting Nectin-4 to clinical proof-of-concept as well as the development of additional ADC programs.
Lead Product(s): ETx-22
Therapeutic Area: Oncology Product Name: ETx-22
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Pontifax Venture Capital
Deal Size: $98.3 million Upfront Cash: Undisclosed
Deal Type: Series A Financing December 07, 2021
Details:
Under the terms of the agreement, Emergence Therapeutics will use a PSARlink™ drug-linker developed by Mablink to develop an ADC targeting Nectin-4, a protein overexpressed in several severe cancers.
Lead Product(s): Antibody-drug Conjugate
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Mablink Bioscience
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 21, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
